| Literature DB >> 30283298 |
Ju Zheng1,2,3, Joris Winderickx2, Vanessa Franssens2, Beidong Liu3,4,5.
Abstract
Huntington's disease (HD) is genetically caused by mutation of the Huntingtin (HTT) gene. At present, the mechanisms underlying the defect of HTT and the development of HD remain largely unclear. However, increasing evidence shows the presence of enhanced oxidative stress in HD patients. In this review article, we focus on the role of oxidative stress in the pathogenesis of HD and discuss mediators and potential mechanisms involved in mutant HTT-mediated oxidative stress generation and progression. Furthermore, we emphasize the role of the unicellular organism Saccharomyces cerevisiae in investigating mutant HTT-induced oxidative stress. Overall, this review article provides an overview of the latest findings regarding oxidative stress in HD and potential therapeutic targets for HD.Entities:
Keywords: Huntingtin; Huntington’s disease; neurodegeneration; oxidative stress; yeast
Year: 2018 PMID: 30283298 PMCID: PMC6156126 DOI: 10.3389/fnmol.2018.00329
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
Figure 1Mutant HTT (mHTT) induced mitochondria-mediated reactive oxygen species (ROS) accumulation. This figure summarizes the mitochondria-associated dysfunction caused by expression of mHTT. mHTT directly contacts the mitochondrial membrane and disturbs calcium homeostasis (Suzuki et al., 2012). mHTT causes mitochondrial dysfunction by damaging mitochondrial DNA (mtDNA; Polidori et al., 1999; Yang et al., 2008). mHTT interrupts mitochondrial fission/fusion and interferes with mitochondrial energy metabolism (Jenkins et al., 1993; Brouillet et al., 1995; Gu et al., 1996; Shirendeb et al., 2011a; Song et al., 2011). Mitochondrial defects result in ROS accumulation, which further leads to apoptosis and cell death.
Figure 2Oxidative stress-associated cellular processes involved in Huntington’s disease (HD) pathogenesis. mHTT acts within the nucleus and either suppresses transcription of critical genes and downregulates mitochondrial function or directly alters the expression level of mitochondrial biogenesis-associated proteins such as PGC-1α. This alteration of the PGC-1α protein level then further regulates the ROS defense system in the cytosol. The mHTT-mitochondria interaction generates ROS through many processes, including Ca2+ leakage through the ryanodine receptor (RyR). Failure of Ca2+ homeostasis triggers the opening of the mitochondrial permeability transition pore (mPTP), which disturbs the ATP level and enables release of cytochrome c. Meanwhile, mitochondrial protein import is impaired due to the binding of mHTT to the TIM23 complex. mtDNA damage and depletion within the mitochondria elevate ROS production. Lastly, cytosolic mHTT inhibits mitochondrial fission–fusion by interacting with Drp1.
Major published oxidative stress-associated processes and mediators of Huntington’s disease (HD) pathogenesis.
| Processes and mediators | Model system | Type of mHTT | Description and consequence | References |
|---|---|---|---|---|
| mtDNA damage | Mouse; Striatal immortalized neuronal cell | Human HTT exon1: 115–150Q; 111Q | mHTT increases mitochondria-generated ROS and decreases mtDNA abundance. | Yang et al. ( |
| mtDNA depletion | Mouse and human HD patient | Human HTT exon1: 144Q; ~160Q | mHTT results in a lower copy number of mtDNA and increases the vulnerability of the striatum. | Petersen et al. ( |
| Ca2+ imbalance | Rat cortical neuron | Truncated N-terminal HTT: 150Q | mHTT induces Ca2+ leakage through the Ca2+ channel RyR, further resulting in opening of the mPTP, which contributes to mitochondrial oxidative stress. | Suzuki et al. ( |
| p53 | HEK293 cell; Mouse and human HD patient | Human HTT exon1+/− proline-rich region: 103Q; N-terminal HTT: 86Q | p53 promotes expression of mHTT and mediates mHTT-induced mitochondrial dysfunction; the mHTT-p53 interaction suppresses transcription of p53-regulated genes. | Steffan et al. ( |
| PGC-1α | Mouse and striatal cell culture | Human HTT exon1 and Mouse HTT: 111Q | mHTT reduces PGC-1α transcription and activity and suppresses downstream targets of PGC-1α, such as ROS defense factors. | Chaturvedi et al. ( |
| Drp1 | Human HD patient; mouse; rat cortical neuron | Human mutant HTT; full-length human mHTT: 97Q; Human HTT exon1: 46 and 97Q | mHTT interacts with Drp1, disrupting the balance of the mitochondrial fission–fusion processes. | Shirendeb et al. ( |
| NOX | Human HD patient and mouse | Mouse HTT: 140Q | Higher levels of brain NOX activity are observed in HD, whereas NOX inhibitors reduce the ROS level and neuronal death. | Valencia et al. ( |
| Mitochondrial enzymes | Human HD patient and mouse | Human HTT exon1: 94Q | Mitochondrial enzymes are oxidatively modified, with decreased catalytic activity and energy deficiency in individuals with HD. | Sorolla et al. ( |
| Vitamin B6 | Human HD patient and mouse | Human HTT exon1: 94Q | Oxidation of pyridoxal kinase and antiquitin 1 decreased the availability of active vitamin B6, leading to the disturbances of neurotransmitters. | Sorolla et al. ( |
| Kynurenine pathway | Yeast | Human HTT exon1 lacking proline-rich region: 103Q | mHTT induces cytotoxicity through the kynurenine pathway and its intermediate product QUIN, which triggers striatal neuronal death via a cascade of events, such as oxidative stress. | Giorgini et al. ( |
| Prx1 | PC12 cell | Human HTT exon1: 103Q | mHTT affects expression of the antioxidant protein Prx1, disturbing the ROS clearance system. | Pitts et al. ( |
| GPxs | Yeast | Human HTT exon1 lacking proline-rich region: 103Q | These antioxidant enzymes protect against ROS production and suppress mHTT toxicity. | Mason et al. ( |
| RQC | Yeast | Human HTT exon1 precence/absence of proline-rich region: 103Q | RQC system regulates mHTT compartmentalization and nucleocytoplasmic translocation that is associated with polyQ cytotoxicity. | Yang et al. ( |